The anti-staphylococcal fusidic acid as an efflux pump inhibitor combined with fluconazole against vaginal candidiasis in mouse model

Salwa E. Gomaa,Hisham A. Abbas,Fatma A. Mohamed,Mohamed A. M. Ali,Tarek M. Ibrahim,Alyaa S. Abdel Halim,Mashael A. Alghamdi,Basem Mansour,Anis Ahmad Chaudhary,Amr Elkelish,Fehmi Boufahja,Wael A. H. Hegazy,Fatma Al-zahraa A. Yehia

DOI: https://doi.org/10.1186/s12866-024-03181-z

IF: 4.465

2024-02-12

BMC Microbiology

Abstract:Candida albicans is the most common fungus that causes vaginal candidiasis in immunocompetent women and catastrophic infections in immunocompromised patients. The treatment of such infections is hindered due to the increasing emergence of resistance to azoles in C. albicans . New treatment approaches are needed to combat candidiasis especially in the dwindled supply of new effective and safe antifungals. The resistance to azoles is mainly attributed to export of azoles outside the cells by means of the efflux pump that confers cross resistance to all azoles including fluconazole (FLC).

microbiology

What problem does this paper attempt to address?

The main problem that this paper attempts to solve is vulvovaginal candidiasis (VVC) caused by Fluconazole (FLC) - resistant Candida albicans. By studying fusidic acid (FA) as an efflux pump inhibitor in combination with Fluconazole, the antifungal activity of Fluconazole is restored or enhanced. Specifically, the research aims to:

1. **Evaluate the efflux pump - inhibiting effect of fusidic acid (FA)**: Through experiments, verify whether FA can inhibit the efflux pump activity in Candida albicans, thereby reducing the efflux of antifungal drugs such as Fluconazole and increasing their intracellular accumulation.

2. **Explore the synergistic effect of the combined use of FA and Fluconazole**: When FA and Fluconazole are used in combination, study whether it can significantly reduce the minimum inhibitory concentration (MIC) of Fluconazole, thereby enhancing its therapeutic effect on resistant Candida albicans.

3. **Evaluate the safety of FA**: Through in vitro experiments (such as hemolysis experiments) and in vivo experiments (such as mouse models), evaluate the cytotoxicity and safety of FA to ensure its safety in clinical applications.

4. **Mechanism research at the molecular level**: Through real - time quantitative PCR and molecular docking studies, explore the influence of FA on the expression of efflux pump genes and its binding mechanism with efflux pump proteins.

In summary, the goal of this research is to develop a new treatment strategy, using FA as an adjuvant drug in combination with the existing antifungal drug Fluconazole, to effectively treat drug - resistant vulvovaginal candidiasis.